October 2026
Longevity research from October 2026, curated and analyzed through the EDGE Framework.
FDA Moves Aging Into Its Regulatory Science Agenda
Senior FDA officials announced at the 2026 Aging Research and Drug Discovery Meeting that aging and longevity will be included in the agency's forthcoming Focus Areas of Regulatory Science update, targeted for fiscal year 2027. Panelists outlined plausible approval pathways for gerotherapeutics, including evidence across multiple age-related conditions or measured slowing of decline in intrinsic capacity. The discussion marks the first substantive regulatory articulation of how a drug might earn a broad aging indication.
TDP-43 Vectorized Antibody Trial Triples ALS Cohort Size
VectorY Therapeutics has tripled enrollment in its Phase 1/2 PIONEER-ALS study of VTx-002, from 12 to 36 participants, before any efficacy readouts. The investigational agent is a vectorized antibody intended to produce sustained intrathecal antibody expression against pathological TDP-43, the protein the company reports aggregates abnormally in up to 97% of ALS patients. The expanded cohort is designed to strengthen the signal from secondary and exploratory endpoints, including neurofilament light chain and TDP-43 pathway biomarker trajectories.
Menopause Care Merges Hormone Therapy With Psychiatric Support
Two telehealth companies have formed a national partnership linking menopause and hormone therapy with integrative psychiatry, including screened, off-label at-home ketamine therapy for women whose depression or anxiety has not responded to prior treatment. The model also expands hormone monitoring and preventive care. It reflects a shift toward treating the endocrine and psychiatric features of perimenopause as a single clinical picture rather than separate referrals.
Ribupatide Phase 3 Fully Enrolled, Semaglutide Head-to-Head
Kailera Therapeutics has completed enrollment of approximately 4,900 adults across three Phase 3 trials of once-weekly ribupatide injection for obesity and overweight, with dosing to 10 mg over 76 weeks. One trial measures weight loss directly against semaglutide 2.4 mg, and another tracks hemoglobin A1c in participants with type 2 diabetes. Topline data are expected in mid-2028.
Mesenchymal Cell Therapy Targets Neuroinflammation and Frailty
Longeveron is presenting at three longevity investment meetings in October while advancing laromestrocel (Lomecel-B), an investigational mesenchymal stem cell therapy not approved by the FDA. A medRxiv preprint describes a post hoc exploratory analysis of the 49-participant Phase 2a CLEAR MIND study suggesting reduced brain neuroinflammation in Alzheimer's disease, and Phase 2b data published in Cell Stem Cell reported improved physical condition in patients with age-related frailty after nine months.
LRRK2 Degrader Crosses Blood-Brain Barrier in Phase 1 Data
Arvinas will present biomarker data from a Phase 1 trial of ARV-102, an orally bioavailable protein degrader designed to cross the blood-brain barrier and eliminate LRRK2, in healthy volunteers and Parkinson's patients. The approach applies targeted protein degradation — removing a disease-associated protein rather than inhibiting it — to a neurodegenerative indication. Results are scheduled for late-breaking presentation at the 2026 International Congress of Parkinson's Disease and Movement Disorders in Seoul.
Memory Precision Testing Paired With Alpha-Synuclein Assays
Amprion and Prema Cognition are linking a 10- to 15-minute digital memory precision test, developed with the University of Cambridge Memory Lab, to seed amplification assays that detect misfolded alpha-synuclein. The intent is a two-stage pathway in which accessible remote or clinic-based cognitive screening identifies candidates for molecular confirmation. Earlier identification of neurodegenerative pathology extends the window in which intervention can meaningfully alter trajectory.
Hepatic Mitochondrial Density Restored Without Appetite Suppression
MitoRx Therapeutics reported preclinical electron microscopy data showing its lead small molecule MTRX31 restored hepatic mitochondrial density in diet-induced obese mice to levels seen in lean controls, while reducing liver lipid droplets and normalizing glycogen handling. The company positions the compound as a non-appetite-suppressing approach to clearing ectopic fat by repairing mitochondrial function rather than restricting intake. If replicated in humans, the approach would target metabolic inflexibility itself, a feature that tracks closely with age-related decline in tissue function.
Oral NEK7 Degrader Cuts hsCRP 85% Without Immune Cost
Monte Rosa Therapeutics reported Phase 1 results for MRT-8102, an oral degrader of NEK7, in 108 obese adults with elevated cardiovascular risk. Four weeks of dosing produced approximately 80–90% NEK7 degradation alongside median reductions of 85% in hsCRP, 54% in IL-6, 28% in fibrinogen and 24% in lipoprotein(a), with adverse event rates comparable to placebo and no signal of increased infection risk.
Brain Volume and Lung Function Outrank Proteomic Organ Clocks
In a 16-year follow-up of 861 older adults, epigenetic age (GrimAge2), brain and grey matter volume, respiratory function and cognitive performance predicted all-cause mortality more strongly than plasma proteomic organ clocks. Among 9703 protein targets, 368 were linked to mortality, with GDF15, WFDC2 and TIMP1 leading; elevated-risk proteins clustered in immune signalling while protective ones mapped to genomic stability and cellular maintenance.
Wnt Signaling Loss Dampens Immune Recruitment in Spinal Discs
Deleting β-catenin in mouse intervertebral disc cells, a model of age-related loss of Wnt signaling, cut expression of the monocyte chemoattractant CCL2 by 58%–79% and reduced myeloid cell burden in uninjured discs by 79%, with injury-induced recruitment falling by 48%. Nucleus pulposus-specific deletion blunted activation of immune signaling pathways after injury on RNA sequencing. Disc resident cells, not infiltrating immune cells, appear to set the chemotactic tone that governs inflammation in the aging spine.
Mitochondrial DNA Leakage Links Lung Inflammation to Muscle Loss
In chronic obstructive pulmonary disease, elevated TNF-α drives p53-dependent upregulation of the mitochondrial enzyme Prodh2 in muscle progenitor cells, generating excess mitochondrial reactive oxygen species and leaking mitochondrial DNA into the cytosol, where it triggers the cGAS/STING innate immune sensor. The resulting apoptosis, proliferation arrest, and atrophy were reversed by muscle-specific Prodh2 knockdown, which restored strength in a mouse model. The work maps a specific molecular route by which chronic inflammation converts into measurable loss of muscle mass and function.
Aged Jellyfish Lose Blastema Formation and Wound Repair Speed
In the medusa stage of the cnidarian Cladonema pacificum, an organism with exceptional regenerative capacity, aging produced progressive structural shrinkage, loss of differentiated neurons and stinging cells, accumulating DNA damage, and depletion of stem cell-associated populations. Aged animals showed delayed wound closure, defective blastema formation, and incomplete tentacle recovery, indicating that regenerative decline is not avoided even in species built for repair. The finding places limits on regeneration as a conserved feature of aging across the animal kingdom rather than a mammal-specific constraint.
Immune Cell Genes Anchor Alzheimer's Risk and Drug Repurposing
An integrative analysis combining single-cell transcriptomic data with Alzheimer's genetic risk loci identifies disease-associated genes expressed in specific immune cell populations, particularly brain-resident and peripheral immune lineages. The resulting gene set is then mapped against existing pharmacological compounds to generate drug repurposing candidates. The work positions immune regulation, rather than amyloid accumulation alone, as a tractable target in neurodegenerative disease.
Aging Biomarkers Face Their Validation Test at Harvard 2026
The Biomarkers of Aging Consortium will convene its fourth annual conference at Harvard Medical School in October 2026, assembling researchers, clinicians, industry developers, regulators, and funders around the validation of aging biomarkers. The central problem addressed is standardization: therapies targeting aging are nearing clinical testing, but the field lacks agreed-upon methods to confirm that an intervention has altered biological aging. Satellite programs extend the agenda into brain aging, reproductive aging, and replacement-based regenerative strategies.
Mitochondrial Repair and Late-Life GLP-1 Lead September Findings
September's aging research centered on mitochondrial quality control, with multiple independent studies linking the clearance and replacement of damaged mitochondria to improvements in cardiac energy handling, skin photoaging, cognitive plasticity, and cellular rescue after immune cell transplantation. Parallel findings included a 12% median lifespan extension in female mice given semaglutide late in life, longer lifespan after midlife suppression of growth hormone receptor production, and new biomarkers for senescent cell burden and epigenetic age responsiveness.
FDA Maps Approval Routes for Therapies Targeting Aging
Senior FDA officials at ARDD 2026 outlined how a therapy targeting aging biology might reach approval, confirming that aging and longevity will appear in the agency's forthcoming focus areas of regulatory science document. Two routes were described: demonstrating benefit across several age-related diseases sequentially, or defining a population with multi-domain age-related decline and measuring composite deterioration. Officials expect the earliest approvable trials to use prevention of age-related comorbidities or mortality as endpoints.
Skin-Derived Dopamine Neurons Sidestep Immunosuppression
Aspen Neuroscience published preclinical data in Cell Stem Cell for sasineprocel, an autologous cell therapy in which a patient's own skin cells are reprogrammed into induced pluripotent stem cells and differentiated into dopaminergic neuron precursors for image-guided delivery to the putamen. Because the graft is genetically matched to the recipient, immunosuppression is not required, though each dose must be verified individually using whole-genome sequencing and a machine-learning RNA-sequencing assay. Preclinical models showed improved motor function and no treatment-related adverse findings over a nine-month GLP safety study; the company's Phase 1/2a trial remains ongoing despite release language referencing Phase 3.
AI-Guided Multidomain Care Plans and Cognitive Stability in MCI
A retrospective analysis of 345 paired cognitive tests found that 83.5% of older adults using an AI-generated multidomain care plan improved, remained stable, or declined more slowly than expected over an average of 14.1 months. The cohort averaged 74.6 years, nine comorbidities, 11.7 medications and 23 clinically significant drug-drug interactions. Without a usual-care comparison group, the stabilization cannot be attributed to the intervention with confidence.
Unsequenced Biology Becomes Training Data for Drug Design
Basecamp Research closed a $140 million Series C to train general-purpose AI models on the Trillion Gene Atlas, a genomic dataset assembled through partnerships across more than 30 countries and all seven continents. Rather than modeling the narrow, heavily studied slice of human and pathogen biology, the company is training on largely unexamined natural sequence diversity to design cell and gene therapies, enzymes and peptides. Its lead application is in vivo cell therapy — reprogramming a patient's own cells inside the body rather than extracting, modifying and reinfusing them.
Longevity Medicine Confronts Its Evidence Gap at Harvard
The 13th Aging Research and Drug Discovery meeting opened at Harvard with Dean George Daley urging that clinical and scientific rigor precede commercial enthusiasm, citing a fatal air embolism at a wellness center as evidence of what unregulated longevity services can cost. US Assistant Secretary for Health Brian Christine framed federal priorities around prevention and modifying biology over time rather than treating conditions one at a time. Regulators acknowledged that consumer demand, including biological age testing, is outpacing institutional guidance.
Oral GLP-1 Elecoglipron Enters Heart and Kidney Outcome Trials
AstraZeneca has begun a global Phase 3 program for elecoglipron, a once-daily oral small-molecule GLP-1 receptor agonist, triggering a $50 million milestone payment to originator Eccogene. Phase 2b data showed 11.8 percent weight loss at 36 weeks and a 1.9 percent HbA1c reduction at 26 weeks, and the Phase 3 design extends beyond weight and glycemia into heart failure with preserved or mildly reduced ejection fraction and chronic kidney disease.
EEG-Based Brain Function Testing Enters Routine Imaging Care
Diagnostic Imaging Centers of Texas is integrating VoxNeuro's FDA-cleared Cognitive Function Neuroimaging software, which applies statistical analysis to EEG and event-related potential data, alongside its MRI, CT and ultrasound services. The pairing adds objective measures of brain function to structural imaging for patients recovering from motor vehicle collisions and workplace injuries. For cognitive longevity, it reflects a shift toward quantifying how the brain is working, not only how it appears.
Microbiome Intervention Data Draws $33M Into Infant Health
Tiny Health closed a $33 million Series B led by B Capital, bringing total funding to $46 million, alongside a $5 million research program directed at translational microbiome work. The company reports a 2025 randomized controlled trial in which a targeted microbiome intervention lowered the odds of infant eczema by 83%, with a second trial underway. Capital is allocated to interventional research, practitioner education, and an AI model trained on nearly 200,000 shotgun metagenomic profiles.
Whole-Body MRI Biobank Quantifies Incidental Brain Findings
Prenuvo has established a research network built on an imaging biobank of more than 200,000 standardized whole-body MRI scans, offering controlled access to de-identified datasets and AI-generated statistical summaries. Four initial studies examine pulmonary and mediastinal findings, incidental brain abnormalities across more than 78,000 screened individuals, structural changes associated with alcohol intake in adults without alcohol use disorder, and renal findings across 117,826 scans. The scale shifts whole-body imaging from individual screening toward population-level characterization of subclinical disease.
AI-Designed Oral GIPR Candidate Moves Toward GLP Toxicology
Insilico Medicine has nominated ISM1354, an orally available small molecule targeting the glucose-dependent insulinotropic polypeptide receptor, as a preclinical candidate for obesity, type 2 diabetes and related cardiometabolic disease. Reported preclinical data include 75-104% oral bioavailability across four species, at least 18-fold greater plasma exposure than a clinical-stage comparator at equivalent dose, and a 45-fold safety margin in non-GLP monkey toxicology. The compound was generated through AI-driven multi-objective molecular design and now moves toward GLP toxicology studies.
60 Compounds Extended Mouse Lifespan in 16,000-Animal Screen
Longevica Therapeutics reports a four-year, $13 million in vivo screening program at The Jackson Laboratory that followed 1,033 small molecules across more than 16,000 mice through their natural lifespans, identifying roughly 60 compounds associated with 10 to 22 percent lifespan extension and two candidate mechanisms. With a new CEO and a newly assembled scientific advisory board, the company states it is moving from data generation to clinical development. Full-lifespan mammalian phenotypic datasets of this scale remain rare and provide a different class of evidence than short-term biomarker studies.
Transcription Factor Reset Moves from Lab to Skincare
Amorepacific and Junevity have formed a licensing and investment partnership to translate transcription factor–based cellular rejuvenation into topical cosmetic products. Junevity's platform combines human disease omics, genetic linkage data and machine learning to identify transcription factor targets, building on published work in which modulating single transcription factors reversed hallmarks of cellular aging in human fibroblasts. The approach shifts skin aging intervention from surface chemistry toward upstream gene network regulation.
Aged Hearts Remodel Less Than Young Hearts After Infarction
Serial cardiac MRI of young and aged mice after permanent coronary ligation found no age-related worsening of post-infarction left ventricular remodeling. Aged animals began with larger chamber volumes, greater diastolic mass, and reduced deformation capacity, while young animals underwent proportionally larger geometric change relative to their own baseline alongside faster histological healing. The results complicate the assumption that advancing age uniformly amplifies adverse ventricular remodeling after myocardial infarction.
Online Training for Dementia Caregiver Burden and Quality of Life
Informal caregivers of people living with dementia carry measurably high burden and diminished quality of life, yet structured training for this population remains sparsely evaluated. This trial assessed whether a remotely delivered training program could reduce caregiver burden and improve quality of life, addressing a gap in which support interventions are widely recommended but rarely tested in accessible formats.
Dementia Narrows the Path Home From Nursing Facilities
Qualitative interviews with nursing home residents and family caregivers examined why people living with dementia transition back to community living less often through Medicaid's Money Follows the Person program. Participants described strong motivation to resume community life, while cognitive impairment introduced additional complexity into planning, consent, and caregiver capacity. The work identifies modifiable barriers in a program designed to restore autonomy and community connection in later life.
Home Care Labor Supply Limits Rural Aging-in-Place Goals
An analysis in the Journal of Applied Gerontology tracks the supply of home-based direct care workers across the United States from 2015 to 2024, comparing rural and urban trends against rising demand driven by population aging and preferences to age in place. The question addressed is whether labor supply is growing fast enough to meet that demand, with particular attention to rural areas where shortfalls are least understood. Workforce availability functions as a determinant of whether older adults can remain in their homes safely as functional capacity declines.